Jun 09, 2021 / 05:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ionis with us. And with us from Ionis is Brett Monia, CEO of the company. Brett, thank you for being here this morning -- this afternoon.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPTo start, could you walk us through the outlook for the remainder of 2021 in terms of key events and data catalysts for the company?
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, CEO & Director
Sure thing, Salveen, and thanks for the invitation. It's a pleasure to be here today. Yes, quite a number of news coming out of Ionis projected for the second half of the year. Data readouts and as well as new study starts.
Of course, the most exciting data readout that we're really looking forward to is the Phase III readout for tofersen in SOD1-ALS. This is a readout
Trustpilot
